Venlafaxine HCl Clinical Trials

Size	Price	Qty
25mg	USD 147

Clinical Trials

Venlafaxine HCl has been evaluated across numerous Phase 1 through Phase 4 clinical trials for psychiatric conditions—such as major depressive, bipolar affective, and obsessive-compulsive disorders—as well as physical ailments including chemotherapy-induced peripheral neuropathy, non-specific low back pain, and rheumatoid arthritis. Sponsored by academic institutions and pharmaceutical entities, these studies encompass recruitment statuses ranging from completed to recruiting and not yet recruiting. Furthermore, pharmacokinetic evaluations have characterized drug disposition in both healthy subjects and patients undergoing bariatric procedures such as gastric bypass.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06106529	RECRUITING	Breast Cancer; Hot Flash Due to Medication	Reinier de Graaf Groep	2024-10-03	PHASE3
NCT07737158	NOT_YET_RECRUITING	Non-specific Low Back Pain; Pain Management	Beijing Tiantan Hospital	2026-09-01
NCT05973786	RECRUITING	Bipolar Depression	Dr. Inge Winter	2025-02-11	PHASE3
NCT05603104	RECRUITING	Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression	Dr. Inge Winter	2025-04-27	PHASE3
NCT07359248	ACTIVE_NOT_RECRUITING	Tension Type Headache	Tongji Hospital	2025-12-01
NCT07698626	NOT_YET_RECRUITING	Bladder Pain Syndrome; Chronic Pelvic Nociplastic Pain; Interstitial Cystitis	Beijing Tiantan Hospital	2026-12-31	PHASE1
NCT07361809	RECRUITING	Herpes Zoster; Pain	Beijing Tiantan Hospital	2025-12-15
NCT07361796	RECRUITING	Herpes Zoster; Pain; Postherpetic Neuralgia	Beijing Tiantan Hospital	2025-12-15
NCT07230171	RECRUITING	Fibromyalgia; Pregabalin; Esketamine	Beijing Tiantan Hospital	2025-09-15
NCT04539951	RECRUITING	Obsessive-Compulsive Disorder	Shanghai Mental Health Center	2020-09-22	PHASE2
NCT07186751	RECRUITING	Fibromyalgia; Pregabalin; Venlafaxine; Pain	Beijing Tiantan Hospital	2025-09-20
NCT07330648	RECRUITING	Generalized Anxiety Disorder	Anhui Medical University	2025-10-10	PHASE2
NCT07025590	RECRUITING	Cardiovascular Diseases (CVD); Depression Anxiety Disorder	Guangdong Provincial People's Hospital	2025-04-22
NCT04961190	ACTIVE_NOT_RECRUITING	Posttraumatic Stress Disorder	University of Pennsylvania	2022-05-25	PHASE4
NCT07497282	NOT_YET_RECRUITING	Rheumatoid Arthritis	Ain Shams University	2026-03-26	PHASE2
NCT05724849	WITHDRAWN	Head and Neck Cancer; Depression	Vanderbilt University Medical Center	2023-08-01	PHASE2
NCT06803485	RECRUITING	Somatic Symptom Disorder (DSM-V)	All India Institute of Medical Sciences, Bhubaneswar	2025-03-11	PHASE4
NCT06508710	RECRUITING	Major Depressive Episode	Assistance Publique - Hôpitaux de Paris	2024-10-20	PHASE3
NCT04973930	SUSPENDED	Major Depressive Disorder; Breast Cancer; Venlafaxine	New York State Psychiatric Institute	2022-03-01	PHASE3
NCT06965569	COMPLETED	Treatment Resistant Depression	Alar Pharmaceuticals Inc.	2025-04-21	PHASE1
NCT06295562	COMPLETED	Obstructive Sleep Apnea of Adult	China Medical University Hospital	2024-11-05	PHASE4
NCT05023278	COMPLETED	Acute Pain; Chronic Pain; Knee Pain Chronic; Neuropathic Pain	University of California, San Francisco	2021-05-10	PHASE4
NCT06278038	COMPLETED	Major Depression Disorder	First Affiliated Hospital of Zhejiang University	2024-02-22
NCT04977271	WITHDRAWN	Depressive Disorder; Head and Neck Cancer	University of Alabama at Birmingham	2024-01-05	PHASE4
NCT05280015	UNKNOWN	Depression; Depressive Disorder; Depressive Disorder, Major	Centre Hospitalier Universitaire de Besancon	2022-06-08	PHASE2
NCT06131268	UNKNOWN	Major Depressive Disorder; Bipolar Affective Disorder, Currently Depressed, Moderate	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	2022-03-01	PHASE4
NCT05884268	UNKNOWN	Laparoscopic Cholecystectomy	Mansoura University	2023-05-30	PHASE1; PHASE2
NCT05875610	UNKNOWN	Peripheral Neuropathy Due to Chemotherapy	Mit Ghamr Oncology Center	2023-05-01	PHASE4
NCT04218123	COMPLETED	Meniere Disease	Medical University of South Carolina	2020-02-05	PHASE2; PHASE3
NCT04664088	UNKNOWN	Vestibular Migraine	Affiliated Hospital of Jiaxing University	2021-01-01
NCT02977299	COMPLETED	Treatment Resistant Major Depressive Disorder	Massachusetts General Hospital	2017-07-13	PHASE4
NCT05104918	UNKNOWN	Major Depressive Disorder	Scotmann Pharmaceuticals	2022-02	PHASE3
NCT06131268	Recruiting	Major Depressive Disorder\|Bipolar Affective Disorder Currently Depressed Moderate	Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico	2022-03-01	Phase 4
NCT04639193	COMPLETED	OSA; Obstructive Sleep Apnea	University of California, San Diego	2020-12-01	PHASE2
NCT05569031	COMPLETED	Opiate Withdrawal Syndrome	Zagazig University	2019-01-01	PHASE4
NCT04207385	UNKNOWN	Depression	Xijing Hospital	2019-12-01	PHASE4
NCT04737967	UNKNOWN	Oncology Pain; Chemotherapy-induced Peripheral Neuropathy	Mendel AI	2021-02-15	PHASE2; PHASE3
NCT03574792	COMPLETED	Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8	Roswell Park Cancer Institute	2018-05-03	PHASE2
NCT03434041	COMPLETED	Depressive Disorder, Treatment-Resistant	Janssen Research & Development, LLC	2018-05-25	PHASE3
NCT04708834	Enrolling by invitation	Obsessive Compulsive Disorder	Biohaven Pharmaceuticals Inc.	2021-03-30	Phase 3
NCT02955719	COMPLETED	Depression; Anxiety; Mild Cognitive Impairment	Centre for Addiction and Mental Health	2016-03-30
NCT04229602	UNKNOWN	Bioequivalence Study	Beijing Tongren Hospital	2020-01-02
NCT02711215	UNKNOWN	Major Depressive Disorder	Medical University of Vienna	2015-05	PHASE4
NCT02590185	UNKNOWN	Major Depressive Disorders	Assistance Publique - Hôpitaux de Paris	2015-12
NCT00693849	UNKNOWN	Major Depressive Disorder	BRC Operations Pty. Ltd.	2008-09	PHASE4
NCT02655354	COMPLETED	Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life; Pain; Wounds and Injury; Brain Injuries; Chronic Disease	University of Washington	2015-10
NCT03274817	TERMINATED	Alzheimer Disease	NYU Langone Health	2009-06-18	PHASE1
NCT03588572	COMPLETED	Subcortical Aphasia; Ischemic Stroke	Guangzhou General Hospital of Guangzhou Military Command	2018-08-01
NCT02051413	COMPLETED	Major Depressive Disorder; Major Depressive Episode	Institut National de la Santé Et de la Recherche Médicale, France	2014-02-18	PHASE4
NCT02181231	COMPLETED	Major Depressive Disorder; Depression	Washington University School of Medicine	2016-06-01	PHASE1; PHASE2
NCT02417064	COMPLETED	Treatment-resistant Depression	Janssen Research & Development, LLC	2015-08-10	PHASE3
NCT02493868	COMPLETED	Depressive Disorder, Treatment-Resistant	Janssen Research & Development, LLC	2015-10-01	PHASE3
NCT02497287	COMPLETED	Treatment-resistant Depression	Janssen Research & Development, LLC	2015-09-30	PHASE3
NCT02422186	COMPLETED	Depressive Disorder, Treatment-Resistant	Janssen Research & Development, LLC	2015-08-20	PHASE3
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT02418585	COMPLETED	Treatment-resistant Depression	Janssen Research & Development, LLC	2015-08-07	PHASE3
NCT02346682	UNKNOWN	Severe Major Depression Disorder	Zhejiang Provincial Tongde Hospital	2015-02	PHASE4
NCT01360866	COMPLETED	Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-10	PHASE3
NCT01824433	COMPLETED	Major Depression	Capital Medical University	2013-03-07	PHASE4
NCT02263248	COMPLETED	Major Depressive Disorder; Depression	Centre for Addiction and Mental Health	2014-12	PHASE1; PHASE2
NCT01557712	COMPLETED	Major Depressive Disorder	University Hospital, Grenoble	2012-03	PHASE3
NCT01609348	COMPLETED	Alzheimer's Disease; Depression	Johns Hopkins University	2012-04
NCT02407704	COMPLETED	Depression; Depressive Disorder, Major; Depressive Disorder; Unipolar Depression; Major Depressive Disorder	Kirk Erickson, PhD	2015-03	PHASE4
NCT03532477	Recruiting	Obesity Morbid	Norwegian University of Science and Technology\|St. Olavs Hospital\|Volvat Medisinsk Senter Stokkan\|Namsos Hospital\|Alesund Hospital	2016-11-02	--
NCT01716377	COMPLETED	Neck Pain	Rhode Island Hospital	2012-10	PHASE2
NCT02637193	COMPLETED	Healthy Subjects	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2015-12	PHASE1
NCT02714400	COMPLETED	Obstructive Sleep Apnea	University of California, San Diego	2016-03	PHASE4
NCT01124188	COMPLETED	Depression; Back Pain	University of Pittsburgh	2010-05	PHASE4
NCT01658228	COMPLETED	Depression; Mild Cognitive Impairment	New York State Psychiatric Institute	2011-09	PHASE4
NCT02433353	WITHDRAWN	Posttraumatic Stress Disorder	Bayne-Jones Army Community Hospital	2016-01	PHASE4
NCT02637193	Completed	Healthy Subjects	Pfizer''s Upjohn has merged with Mylan to form Viatris Inc.\|Pfizer	2015-12	Phase 1
NCT01028508	COMPLETED	Depression	Icahn School of Medicine at Mount Sinai	2010-01	PHASE4
NCT00926835	TERMINATED	Major Depressive Disorder	Ministry of Health & Welfare, Korea	2009-05	PHASE4
NCT02005107	COMPLETED	Roux en Y Gastric Bypass; Sleeve Gastrectomy	North Dakota State University	2013-12	PHASE4
NCT01867255	COMPLETED	Bariatric Surgery; Gastric Bypass; Roux-en-Y Gastric Bypass	Mayo Clinic	2013-10	PHASE1
NCT02237937	UNKNOWN	Major Depression	HolsboerMaschmeyer NeuroChemie GmbH	2011-09	PHASE4
NCT01569685	COMPLETED	Post Traumatic Stress Disorder; Depression	Charlotte Sonne	2012-04	PHASE4
NCT01764867	UNKNOWN	Major Depressive Disorder	Shanghai Mental Health Center	2012-06	PHASE4
NCT02451475	COMPLETED	Fibromyalgia	Mansoura University	2013-02	PHASE1; PHASE2
NCT01977378	UNKNOWN	Major Depressive Disorder	Jiangsu Hansoh Pharmaceutical Co., Ltd.	2013-10	PHASE2; PHASE3
NCT02350985	COMPLETED	Vestibular Migraine	Haseki Training and Research Hospital	2014-01	PHASE4
NCT00892047	COMPLETED	Depression	University of Pittsburgh	2009-08	PHASE4
NCT01896349	UNKNOWN	Treatment Resistant Depression	Hospital de Clinicas de Porto Alegre	2013-04
NCT00974155	COMPLETED	Depression	K. Lieb	2009-09	PHASE4
NCT00253266	COMPLETED	Depression	Max-Planck-Institute of Psychiatry	2008-04	PHASE4
NCT02179268	COMPLETED	Bone Mineral Density Quantitative Trait Locus 7	Guiyang Medical University	2012-03	PHASE3
NCT02086929	COMPLETED	Major Depressive Disorder	Aziende Chimiche Riunite Angelini Francesco S.p.A	2012-12	PHASE3
NCT01611155	COMPLETED	Peripheral Neuropathy	Mayo Clinic	2012-02-17
NCT01441440	COMPLETED	Major Depressive Disorder	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2011-11	PHASE3
NCT01533753	TERMINATED	Prostate Cancer	University of Wisconsin, Madison	2012-02	PHASE2
NCT01485887	COMPLETED	Major Depressive Disorder	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2012-01	PHASE3
NCT02005107	Completed	Roux en Y Gastric Bypass\|Sleeve Gastrectomy	North Dakota State University\|Neuropsychiatric Research Institute Fargo North Dakota	2013-12	Phase 4
NCT01867255	Completed	Bariatric Surgery\|Gastric Bypass\|Roux-en-Y Gastric Bypass	Mayo Clinic	2013-10	Phase 1
NCT01571453	COMPLETED	Major Depressive Disorder	H. Lundbeck A/S	2012-05	PHASE3
NCT01436643	TERMINATED	Depression; Relapsing-remitting Multiple Sclerosis	Novartis Pharmaceuticals	2011-11	PHASE4
NCT00602537	COMPLETED	Bipolar Disorder; Depression	University of Pennsylvania	2007-12	PHASE4
NCT01418209	COMPLETED	Hot Flashes; Menopause; Vasomotor Disturbance	Fred Hutchinson Cancer Center	2011-11
NCT01370304	UNKNOWN	Depression	Xijing Hospital	2011-06	PHASE3
NCT00592384	COMPLETED	Major Depressive Disorder; Dysthymia; Spinal Cord Injuries	University of Washington	2007-07	PHASE4
NCT00714090	COMPLETED	Unipolar Depression	Club rTMS et Psychiatrie	2008-05	PHASE3
NCT00735670	COMPLETED	Spinal Cord Injury	University of Michigan	2008-06
NCT00627887	COMPLETED	Depressive Disorder, Major	Örebro County Council	2008-01	PHASE4
NCT01350921	COMPLETED	Drug Drug Interaction	AstraZeneca	2011-05	PHASE1
NCT01000623	COMPLETED	Hot Flashes	Mayo Clinic	2010-01-31
NCT01443520	COMPLETED	Healthy	Turku University Hospital	2011-10	PHASE4
NCT01114698	TERMINATED	Depression	Janssen Research & Development, LLC	2011-03	PHASE2
NCT00282828	COMPLETED	Social Phobia	Massachusetts General Hospital	2006-03	PHASE4
NCT00967707	COMPLETED	Post-traumatic Neuropathic Pain	Uppsala University	2009-08	PHASE2
NCT01235338	COMPLETED	Healthy	Shire	2010-10-28	PHASE1
NCT00131456	COMPLETED	Depression; Marijuana Abuse	New York State Psychiatric Institute	2004-03	PHASE2
NCT01204086	UNKNOWN	Major Depressive Disorder; Antidepressive Agents; Pharmacogenetics; Venlafaxine; Fluoxetine	National Cheng-Kung University Hospital	2007-03	PHASE4
NCT00354432	TERMINATED	Hot Flashes; Prostate Cancer	Wake Forest University Health Sciences	2007-02-01	PHASE3
NCT00612807	COMPLETED	Major Depressive Disorder; Partner Relational Disorder (V61.10)	Duke University	2006-07	PHASE1; PHASE2
NCT00909155	COMPLETED	Major Depressive Disorder	University of Wisconsin, Madison	2002-07
NCT00150839	COMPLETED	Depressive Disorder, Major	University of Erlangen-Nürnberg Medical School	2006-03	PHASE4
NCT00086190	COMPLETED	Parkinson Disease; Depression	University of Rochester	2005-06	PHASE3
NCT00177671	COMPLETED	Depression; Dementia	University of Pittsburgh	2003-12	PHASE4
NCT00590863	COMPLETED	Major Depressive Disorder	National Institute of Mental Health (NIMH)	2008-03	PHASE4
NCT00183274	COMPLETED	Anxiety Disorders	University of Pennsylvania	2004-01	PHASE4
NCT00789854	COMPLETED	Major Depressive Disorder; Treatment Resistant Depression	AstraZeneca	2008-11	PHASE3
NCT00788944	COMPLETED	Depression	Wyeth is now a wholly owned subsidiary of Pfizer	2008-10	PHASE4
NCT00435279	COMPLETED	Major Depressive Disorder; Insomnia	Sumitomo Pharma America, Inc.	2007-06	PHASE3
NCT00211809	TERMINATED	Body Dysmorphic Disorder	Icahn School of Medicine at Mount Sinai	2008-09	PHASE4
NCT00200902	COMPLETED	Depression	University of California, Los Angeles	2005-08	PHASE4
NCT00043550	COMPLETED	Depression	University of Pennsylvania	2001-11	PHASE3
NCT00584974	COMPLETED	Depressive Disorder, Major	Sumitomo Pharma America, Inc.	2007-12	PHASE2
NCT00248612	COMPLETED	Alcohol-Related Disorders; Anxiety Disorders	Boston Medical Center	2003-09	PHASE2; PHASE3
NCT00634283	COMPLETED	Depression	University of California, Los Angeles	2008-02	PHASE4
NCT00766870	TERMINATED	Major Depressive Disorder	H. Lundbeck A/S	2008-09	PHASE2
NCT00448058	COMPLETED	Depressive Disorder	GlaxoSmithKline	2007-04	PHASE2
NCT00727064	COMPLETED	Healthy	Wyeth is now a wholly owned subsidiary of Pfizer	2008-06	PHASE1
NCT00676039	COMPLETED	Healthy	University of Ottawa	2007-11	PHASE1
NCT00474708	COMPLETED	Major Depressive Disorder	Wyeth is now a wholly owned subsidiary of Pfizer	2007-04	PHASE4
NCT00620776	COMPLETED	Generalized Anxiety Disorder	University of Pennsylvania	2006-10	PHASE2
NCT01011751	COMPLETED	Adenocarcinoma, Prostate	Takeda	2004-04	PHASE3
NCT00084669	COMPLETED	Breast Cancer; Hot Flashes; Sleep Disorders	Massachusetts General Hospital	2004-05
NCT00205491	COMPLETED	TBI (Traumatic Brain Injury)	Virginia Commonwealth University	2004-10	PHASE4
NCT00839423	COMPLETED	Major Depressive Disorder	H. Lundbeck A/S	2006-08	PHASE2
NCT00167856	COMPLETED	Neuropathic Pain; Pain; Spinal Cord Injuries	US Department of Veterans Affairs	2005-06
NCT00329186	COMPLETED	Healthy	Wyeth is now a wholly owned subsidiary of Pfizer	2006-05	PHASE3
NCT00018902	COMPLETED	Depression	University of Pittsburgh	2001-01	PHASE2; PHASE3
NCT00611676	COMPLETED	Osteoarthritis; Pain	University of Washington	2004-09	PHASE4
NCT00045916	COMPLETED	Depression; Depressive Disorder; Bipolar Disorder	New York State Psychiatric Institute	2001-02	PHASE4
NCT00641927	COMPLETED	Bipolar Type II Disorder	Stanley Medical Research Institute	2002-04	PHASE4
NCT00362271	COMPLETED	Healthy	Otsuka Pharmaceutical Development & Commercialization, Inc.	2006-08	PHASE1
NCT00744406	COMPLETED	Depression; Major Depressive Disorder	Centre for Addiction and Mental Health	2003-07	PHASE2
NCT00057642	COMPLETED	Depression; Depressive Disorder	New York State Psychiatric Institute	2002-09
NCT00871364	COMPLETED	Healthy	Actavis Inc.	2006-04	PHASE1
NCT01512459	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2006-05	PHASE1
NCT00186264	COMPLETED	Depressive Disorder, Major	Stanford University	2002-08
NCT00195598	COMPLETED	Panic Disorders	Wyeth is now a wholly owned subsidiary of Pfizer	2005-01	PHASE3
NCT00030914	COMPLETED	Hot Flashes	Alliance for Clinical Trials in Oncology	2002-04	PHASE3
NCT00198250	COMPLETED	Breast Cancer	Indiana University	2000-05	PHASE2
NCT00759122	COMPLETED	Major Depressive Disorder	University of California, Los Angeles	2002-11	PHASE4
NCT00046020	COMPLETED	Depressive Disorder, Major; Recurrence	Wyeth is now a wholly owned subsidiary of Pfizer	2000-08	PHASE4
NCT00316160	COMPLETED	Depressive Disorder, Major; Major Depressive Disorder (MDD)	GlaxoSmithKline	2004-09	PHASE4
NCT00087737	COMPLETED	Major Depressive Disorder	Wyeth is now a wholly owned subsidiary of Pfizer		PHASE3
NCT00090649	COMPLETED	Major Depressive Disorder	Wyeth is now a wholly owned subsidiary of Pfizer		PHASE3
NCT00249483	COMPLETED	Cocaine-Related Disorders	New York State Psychiatric Institute	1999-10	PHASE2
NCT00177528	COMPLETED	Depression	University of Pittsburgh	2000-10	PHASE4
NCT00083980	TERMINATED	Anxiety Disorders	National Center for Complementary and Integrative Health (NCCIH)	2002-06	PHASE2
NCT00044772	COMPLETED	Panic Disorder	Wyeth is now a wholly owned subsidiary of Pfizer	2001-11	PHASE3
NCT01282814	COMPLETED	Healthy	Teva Pharmaceuticals USA	2003-02	PHASE1
NCT00038896	COMPLETED	Panic Disorder	Wyeth is now a wholly owned subsidiary of Pfizer	2001-04	PHASE3
NCT00834249	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-12	PHASE1
NCT00834964	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-12	PHASE1
NCT01260896	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-09	PHASE1
NCT01282801	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-09	PHASE1
NCT00759317	COMPLETED	Depression	University of California, Los Angeles	2001-06	PHASE4
NCT00792168	COMPLETED	Major Depression	University of California, Los Angeles	1996-11	PHASE4
NCT00071695	COMPLETED	Depression	Eli Lilly and Company	2003-07	PHASE4
NCT01418612	COMPLETED	Healthy	Torrent Pharmaceuticals Limited		PHASE1
NCT00115362	COMPLETED	Dyspepsia	Radboud University Medical Center	2005-07
NCT00151450	COMPLETED	Anxiety	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2005-03	PHASE3
NCT00188643	COMPLETED	Bipolar Disorder	University Health Network, Toronto	2002-01	PHASE4
NCT00179283	COMPLETED	Major Depressive Disorder	Vanderbilt University	2002-04	PHASE3
NCT00177567	COMPLETED	Bipolar Disorder	University of Pittsburgh	2001-07	PHASE4
NCT00122850	COMPLETED	Anxiety Disorders	Eli Lilly and Company	2004-10	PHASE3
NCT00546494	COMPLETED	Depression	Wyeth is now a wholly owned subsidiary of Pfizer	2004-02	PHASE4
NCT00238719	COMPLETED	Social Anxiety Disorder	Wyeth is now a wholly owned subsidiary of Pfizer	1999-12	PHASE3
NCT00546923	COMPLETED	Anxiety Disorders; Depression	Wyeth is now a wholly owned subsidiary of Pfizer	2004-08	PHASE4
NCT00122837	COMPLETED	Anxiety Disorder	Eli Lilly and Company	2005-04	PHASE3
NCT00401726	COMPLETED	Depressive Disorder, Major	Wyeth is now a wholly owned subsidiary of Pfizer	2006-06	PHASE4
NCT00080158	COMPLETED	Depression; Suicide, Attempted	New York State Psychiatric Institute	2004-03	PHASE2; PHASE3
NCT00644982	COMPLETED	Depressive Disorder, Major	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2002-10	PHASE4
NCT00067912	COMPLETED	Depression	Eli Lilly and Company	2003-04	PHASE4
NCT00001483	COMPLETED	Bipolar Disorder; Depressive Disorder	National Institute of Mental Health (NIMH)	1995-06	PHASE2
NCT00159146	TERMINATED	Major Depression	Hillerod Hospital, Denmark	2002-08
NCT01418625	COMPLETED	Healthy	Torrent Pharmaceuticals Limited		PHASE1
NCT00351910	COMPLETED	Major Depressive Disorder	AstraZeneca	2006-05	PHASE3

(data from https://clinicaltrials.gov, updated on 2025-02-04)

Check the Venlafaxine HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Venlafaxine acts as a dual serotonin-norepinephrine reuptake inhibitor by selectively binding to presynaptic serotonin and norepinephrine transporters, which blocks monoamine reuptake into presynaptic neurons and enhances synaptic monoaminergic signaling in the central nervous system. This sustained increase in neurotransmitter availability modulates neural circuits responsible for mood and pain perception, establishing its therapeutic efficacy in clinical trials for major depressive disorder and chronic pain conditions.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).